DBH (Dopamine beta-hydroxylase) variants and mutations
DBH (also known as Dopamine beta-hydroxylase) is a human protein-coding gene encoding a dopamine beta-hydroxylase protein. It converts dopamine to norepinephrine inside catecholamine-containing secretory vesicles, making it essential for sympathetic and noradrenergic neurotransmission. Biallelic loss-of-function variants cause dopamine beta-hydroxylase deficiency with profound orthostatic hypotension and autonomic dysfunction. This analysis covers 1,218 DBH variants and mutations. Of these, 96% have computational variant effect predictions. Disease context includes orthostatic hypotension 1, hypertensive disorder, and essential hypertension. Example DBH variants include P2A, P2S, and P2P.
Variant analysis overview
- Gene: DBH
- Protein: Dopamine beta-hydroxylase
- UniProt accession: P09172
- Organism: Homo sapiens
- Variants analyzed: 1218
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 899 unspecified-consequence records; 151 missense variants; 132 synonymous variants; 18 frameshift variants; 1 in-frame insertions; 4 in-frame deletions; 7 stop-gained variants; 5 splice-region variants; 2 substitution
- Prediction scores: 1,168 variants have prediction scores (96% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: orthostatic hypotension 1, hypertensive disorder, essential hypertension, cardiovascular disorder, response to xenobiotic stimulus, hereditary disease, hypertension, pregnancy-induced, nicotine dependence, response to bronchodilator, diabetes mellitus, Disorder of lipid metabolism, Sensorineural hearing impairment.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 6 binding sites; 4 post-translational modification sites.
- Structural context: 374 variants have structural context.
- PTM context: 8 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable DBH variants
Examples include P2A, P2S, P2P, A3S, A3T, A3P, A3V, A3A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- P2A (p.Pro2Ala), gnomAD rs1438146018, REVEL 0.07, CADD 3.63
- P2S (p.Pro2Ser), gnomAD 9-133636375-C-T, REVEL 0.07, CADD 6.16
- P2P (p.Pro2Pro), rs199920333, gnomAD 9-133636377-C-A, CADD 0.79
- A3S (p.Ala3Ser), rs758863303, ClinGen CA375406024, ClinVar RCV002936085, ExAC rs758863303, REVEL 0.04, MetaLR 0.06, Uncertain significance, Inborn genetic diseases
- A3T (p.Ala3Thr), ExAC rs758863303, TOPMed rs758863303, gnomAD rs758863303, REVEL 0.04, MetaLR 0.07, Uncertain significance
- A3P (p.Ala3Pro), gnomAD 9-133636377-CG-C, CADD 21.40
- A3V (p.Ala3Val), gnomAD 9-133636379-C-T, REVEL 0.05, MetaLR 0.07
- A3A (p.Ala3Ala), rs1229611113, gnomAD 9-133636380-C-T, CADD 3.23
- L4F (p.Leu4Phe), rs2538334073, ClinGen CA375406049, ClinVar RCV002667116, REVEL 0.03, MetaLR 0.07, Uncertain significance, Orthostatic hypotension 1
- L4S (p.Leu4Ser), gnomAD 9-133636378-GC-G, CADD 10.50
- S5C (p.Ser5Cys), ExAC rs778274517, gnomAD rs778274517, REVEL 0.01, MetaLR 0.06
- S5G (p.Ser5Gly), ExAC rs778274517, gnomAD rs778274517, REVEL 0.02, MetaLR 0.06
- S5I (p.Ser5Ile), gnomAD rs1357908813, REVEL 0.01, MetaLR 0.06
- S5R (p.Ser5Arg), gnomAD 9-133636384-A-C, REVEL 0.01, MetaLR 0.05
- R6C (p.Arg6Cys), 1000Genomes rs111514228, ExAC rs111514228, TOPMed rs111514228, gnomAD rs111514228, REVEL 0.04, MetaLR 0.04, Uncertain significance
- R6G (p.Arg6Gly), 1000Genomes rs111514228, ExAC rs111514228, TOPMed rs111514228, gnomAD rs111514228, REVEL 0.04, MetaLR 0.05, Uncertain significance
- R6H (p.Arg6His), rs781667738, ClinGen CA5312930, ClinVar RCV001220018, ClinVar RCV002562493, REVEL 0.04, MetaLR 0.07, Uncertain significance, Inborn genetic diseases; Orthostatic hypotension 1
- R6S (p.Arg6Ser), rs111514228, ClinGen CA5312928, ClinVar RCV001168665, 1000Genomes rs111514228, REVEL 0.07, MetaLR 0.04, Uncertain significance, Orthostatic hypotension 1
- R6P (p.Arg6Pro), gnomAD 9-133636388-G-C, REVEL 0.15, MetaLR 0.05
- R6L (p.Arg6Leu), gnomAD 9-133636388-G-T, REVEL 0.03, MetaLR 0.07
- R6R (p.Arg6Arg), gnomAD 9-133636389-C-T, CADD 2.34
- W7* (p.Trp7Ter), NCI-TCGA TCGA novel, CADD 35.00, Variant assessed as somatic; high impact.
- W7L (p.Trp7Leu), NCI-TCGA TCGA novel, REVEL 0.16, MetaLR 0.05, Variant assessed as somatic; moderate impact.
- W7R (p.Trp7Arg), gnomAD 9-133636390-T-C, REVEL 0.04, MetaLR 0.04
- A8S (p.Ala8Ser), ExAC rs746061650, gnomAD rs746061650, REVEL 0.02, MetaLR 0.05
- A8T (p.Ala8Thr), ExAC rs746061650, gnomAD rs746061650, REVEL 0.03, MetaLR 0.05
- A8V (p.Ala8Val), TOPMed rs959727837, REVEL 0.01, MetaLR 0.08
- S9I (p.Ser9Ile), NCI-TCGA Cosmic COSV9970, REVEL 0.06, MetaLR 0.11, Variant assessed as somatic; moderate impact.
- S9N (p.Ser9Asn), rs1191237522, ClinGen CA375406198, NCI-TCGA Cosmic COSV9970, ClinVar RCV002033649, REVEL 0.03, MetaLR 0.11, Uncertain significance, Orthostatic hypotension 1
- S9R (p.Ser9Arg), NCI-TCGA Cosmic COSV5504, NCI-TCGA Cosmic COSV9970, Ensembl rs373639922, REVEL 0.03, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- S9S (p.Ser9Ser), rs1247677192, gnomAD 9-133636398-C-T, CADD 0.66
- L10L (p.Leu10Leu), rs1448578798, gnomAD 9-133636401-G-T, CADD 1.36
- P11S (p.Pro11Ser), ExAC rs770187471, TOPMed rs770187471, gnomAD rs770187471, REVEL 0.02, MetaLR 0.08
- P11T (p.Pro11Thr), gnomAD 9-133636402-C-A, REVEL 0.10, MetaLR 0.18
- P11P (p.Pro11Pro), rs780246471, gnomAD 9-133636404-C-G, CADD 4.35
- G12D (p.Gly12Asp), NCI-TCGA Cosmic COSV5504, NCI-TCGA Cosmic COSV9970, MetaLR 0.06, MetaSVM -1.07, Variant assessed as somatic; moderate impact.
- G12S (p.Gly12Ser), rs5318, UniProt VAR 048838, ESP rs5318, ExAC rs5318, REVEL 0.05, MetaLR 0.02
- G12R (p.Gly12Arg), gnomAD 9-133636405-G-C, REVEL 0.07, MetaLR 0.05
- G12V (p.Gly12Val), gnomAD 9-133636406-G-T, REVEL 0.03, MetaLR 0.07
- G12G (p.Gly12Gly), rs1162644201, gnomAD 9-133636407-C-T, CADD 4.08
- P13R (p.Pro13Arg), gnomAD rs1832052631, REVEL 0.10, MetaLR 0.12
- P13T (p.Pro13Thr), 1000Genomes rs201797804, ExAC rs201797804, TOPMed rs201797804, gnomAD rs201797804, REVEL 0.06, MetaLR 0.09
- P13P (p.Pro13Pro), gnomAD 9-133636410-C-T, CADD 6.13
- S14A (p.Ser14Ala), gnomAD 9-133636406-GC-G, CADD 21.50
- S14N (p.Ser14Asn), gnomAD 9-133636412-G-A, REVEL 0.07, MetaLR 0.10
- S14R (p.Ser14Arg), gnomAD 9-133636413-C-A, REVEL 0.04, MetaLR 0.06
- M15R (p.Met15Arg), gnomAD rs751081253, REVEL 0.15, MetaLR 0.11
- M15T (p.Met15Thr), gnomAD rs751081253, REVEL 0.15, MetaLR 0.09
- M15V (p.Met15Val), Ensembl rs2131281075, REVEL 0.06, MetaLR 0.05
- M15I (p.Met15Ile), gnomAD 9-133636416-G-C, REVEL 0.07, MetaLR 0.08
- R16Q (p.Arg16Gln), rs963604579, ClinGen CA200951555, ClinVar RCV001906961, Ensembl rs963604579, REVEL 0.15, MetaLR 0.12, Uncertain significance, Orthostatic hypotension 1
- R16W (p.Arg16Trp), rs13306306, NCI-TCGA Cosmic COSV5504, ExAC rs13306306, TOPMed rs13306306, REVEL 0.20, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- R16R (p.Arg16Arg), rs13306306, gnomAD 9-133636417-C-A, CADD 1.93
- R16L (p.Arg16Leu), gnomAD 9-133636418-G-T, REVEL 0.28, MetaLR 0.15
- E17K (p.Glu17Lys), gnomAD rs1318047442, MetaLR 0.22, MetaSVM -0.61
- E17R (p.Glu17Arg), gnomAD 9-133636417-CG-C, CADD 23.90
- E17G (p.Glu17Gly), rs769637610, gnomAD 9-133636417-C-CG, CADD 24.20
- E17E (p.Glu17Glu), rs1364028360, gnomAD 9-133636422-G-A, CADD 4.63
- E17D (p.Glu17Asp), gnomAD 9-133636422-G-T, REVEL 0.10, MetaLR 0.12
- A18S (p.Ala18Ser), gnomAD 9-133636423-G-T, REVEL 0.12, MetaLR 0.14
- A18V (p.Ala18Val), gnomAD 9-133636424-C-T, REVEL 0.14, MetaLR 0.06
- A19G (p.Ala19Gly), gnomAD rs1300266314, REVEL 0.14, MetaLR 0.14
- A19V (p.Ala19Val), gnomAD 9-133636427-C-T, REVEL 0.12, MetaLR 0.11
- A19A (p.Ala19Ala), gnomAD 9-133636428-C-G, CADD 1.67
- M21R (p.Met21Arg), rs770621845, ClinGen CA375406573, ClinVar RCV003863216, AlphaMissense 0.19, MetaLR 0.18, Uncertain significance, Orthostatic hypotension 1
- M21T (p.Met21Thr), rs770621845, ClinGen CA5312940, ClinVar RCV002007764, ExAC rs770621845, REVEL 0.32, AlphaMissense 0.19, Uncertain significance, Orthostatic hypotension 1
- M21V (p.Met21Val), rs1381096496, ClinGen CA375406557, ClinVar RCV001168666, gnomAD rs1381096496, REVEL 0.12, MetaLR 0.13, Uncertain significance, Orthostatic hypotension 1
- M21I (p.Met21Ile), gnomAD 9-133636434-G-T, REVEL 0.13, MetaLR 0.14
- Y22H (p.Tyr22His), ExAC rs776539329, TOPMed rs776539329, gnomAD rs776539329, REVEL 0.42, MetaLR 0.32
- Y22N (p.Tyr22Asn), gnomAD 9-133636435-T-A, REVEL 0.55, MetaLR 0.32
- Y22Y (p.Tyr22Tyr), rs564703488, gnomAD 9-133636437-C-T, CADD 2.87
- S23I (p.Ser23Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S23N (p.Ser23Asn), gnomAD rs1203472021, MetaLR 0.08, MetaSVM -1.02
- T24R (p.Thr24Arg), gnomAD rs1832053124, REVEL 0.39, MetaLR 0.31
- T24T (p.Thr24Thr), rs756815809, gnomAD 9-133636443-A-G, CADD 1.02
- A25T (p.Ala25Thr), Ensembl rs2131281112, REVEL 0.16, MetaLR 0.11
- A25V (p.Ala25Val), gnomAD rs1465499287, REVEL 0.04, MetaLR 0.10
- A25S (p.Ala25Ser), gnomAD 9-133636444-G-T, REVEL 0.12, MetaLR 0.10
- V26M (p.Val26Met), rs76856960, ClinGen CA5312943, ClinVar RCV000960610, ClinVar RCV003883513, REVEL 0.14, MetaLR 0.14, Benign/Likely benign, Orthostatic hypotension 1; not specified; not provided
- V26V (p.Val26Val), rs1249628400, gnomAD 9-133636449-G-A, CADD 9.61
- A27T (p.Ala27Thr), gnomAD 9-133636450-G-A, REVEL 0.14, MetaLR 0.28
- A27V (p.Ala27Val), gnomAD 9-133636451-C-T, REVEL 0.13, MetaLR 0.22
- I28N (p.Ile28Asn), Ensembl rs1832053264
- I28V (p.Ile28Val), Ensembl rs2131281118, MetaLR 0.02, MetaSVM -1.03
- I28I (p.Ile28Ile), gnomAD 9-133636455-C-T, CADD 8.95
- F29S (p.Phe29Ser), Ensembl rs1564206873, REVEL 0.26, MetaLR 0.21
- p.Phe29 Leu30insMetValIleLeuValA, gnomAD 9-133636454-T-TCT, CADD 15.90
- F29F (p.Phe29Phe), rs1832053358, gnomAD 9-133636458-C-T, CADD 10.80
- L30Q (p.Leu30Gln), ExAC rs762462999, gnomAD rs762462999, REVEL 0.32, MetaLR 0.25
- L30L (p.Leu30Leu), rs368414868, gnomAD 9-133636459-C-T, CADD 9.51
- V31F (p.Val31Phe), Ensembl rs930083685, REVEL 0.27, MetaLR 0.18
- I32N (p.Ile32Asn), gnomAD rs1368994812, REVEL 0.38, MetaLR 0.27
- I32F (p.Ile32Phe), gnomAD 9-133636465-A-T, REVEL 0.21, MetaLR 0.16
- I32V (p.Ile32Val), gnomAD 9-133636465-A-G, REVEL 0.14, MetaLR 0.14
- I32T (p.Ile32Thr), gnomAD 9-133636466-T-C, REVEL 0.23, MetaLR 0.21
- L33P (p.Leu33Pro), gnomAD rs1832053524, REVEL 0.76, MetaLR 0.36
- L33V (p.Leu33Val), gnomAD 9-133636468-C-G, REVEL 0.26, MetaLR 0.30
- L33L (p.Leu33Leu), gnomAD 9-133636468-C-T, CADD 9.08
- V34A (p.Val34Ala), NCI-TCGA TCGA novel, MetaLR 0.18, MetaSVM -0.72, Variant assessed as somatic; moderate impact.
- V34L (p.Val34Leu), ExAC rs764517520, TOPMed rs764517520, gnomAD rs764517520, REVEL 0.06, MetaLR 0.13
- V34M (p.Val34Met), gnomAD 9-133636471-G-A, REVEL 0.22, MetaLR 0.26
- V34V (p.Val34Val), gnomAD 9-133636473-G-A, CADD 9.43
- A35D (p.Ala35Asp), NCI-TCGA Cosmic COSV5504, Variant assessed as somatic; moderate impact.
- A35V (p.Ala35Val), gnomAD rs1156299871, MetaLR 0.11, MetaSVM -0.97
- A35A (p.Ala35Ala), rs140025171, gnomAD 9-133636476-C-T, CADD 4.50
- A36E (p.Ala36Glu), gnomAD rs1322194341, MetaLR 0.17, MetaSVM -0.62
- A36S (p.Ala36Ser), NCI-TCGA Cosmic COSV5504, REVEL 0.05, MetaLR 0.10, Uncertain significance, Inborn genetic diseases
- A36T (p.Ala36Thr), rs143544421, ClinGen CA5312948, NCI-TCGA Cosmic COSV5504, ClinVar RCV001945728, REVEL 0.14, MetaLR 0.12, Uncertain significance, Orthostatic hypotension 1
- A36V (p.Ala36Val), gnomAD rs1322194341, REVEL 0.08, MetaLR 0.11
- A36A (p.Ala36Ala), rs1399511922, gnomAD 9-133636479-A-C, CADD 1.09
- L37L (p.Leu37Leu), rs767747480, gnomAD 9-133636480-C-T, CADD 7.56
- Q38R (p.Gln38Arg), gnomAD 9-133636484-A-G, REVEL 0.14, MetaLR 0.11
- Q38H (p.Gln38His), gnomAD 9-133636485-G-C, REVEL 0.13, MetaLR 0.21
- G39D (p.Gly39Asp), NCI-TCGA Cosmic COSV9970, REVEL 0.28, MetaLR 0.31, Variant assessed as somatic; moderate impact.
- G39S (p.Gly39Ser), NCI-TCGA Cosmic COSV9970, MetaLR 0.19, MetaSVM -0.73, Variant assessed as somatic; moderate impact.
- G39V (p.Gly39Val), 1000Genomes rs562042962, TOPMed rs562042962, REVEL 0.32, MetaLR 0.29
- G39C (p.Gly39Cys), gnomAD 9-133636486-G-T, REVEL 0.29, MetaLR 0.29
- G39G (p.Gly39Gly), rs1395839860, gnomAD 9-133636488-C-T, CADD 5.96
- S40* (p.Ser40Ter), NCI-TCGA Cosmic COSV5503, CADD 35.00, Variant assessed as somatic; high impact.
- S40L (p.Ser40Leu), rs755891058, NCI-TCGA Cosmic COSV5503, ExAC rs755891058, TOPMed rs755891058, REVEL 0.07, MetaLR 0.10, Variant assessed as somatic; moderate impact.
- S40S (p.Ser40Ser), rs200378894, gnomAD 9-133636491-G-A, CADD 0.03
- A41P (p.Ala41Pro), TOPMed rs1227149719, gnomAD rs1227149719
- A41T (p.Ala41Thr), TOPMed rs1227149719, gnomAD rs1227149719, REVEL 0.06, MetaLR 0.09
- A41V (p.Ala41Val), Ensembl rs1832053998, MetaLR 0.10, MetaSVM -1.02
- P42L (p.Pro42Leu), rs547488212, NCI-TCGA Cosmic COSV5504, 1000Genomes rs547488212, ExAC rs547488212, REVEL 0.11, MetaLR 0.13, Variant assessed as somatic; moderate impact.
- P42S (p.Pro42Ser), Ensembl rs1832054060, REVEL 0.21, MetaLR 0.18
- P42T (p.Pro42Thr), NCI-TCGA Cosmic COSV9970, MetaLR 0.24, MetaSVM -0.71, Variant assessed as somatic; moderate impact.
- R43C (p.Arg43Cys), 1000Genomes rs146820764, ESP rs146820764, ExAC rs146820764, TOPMed rs146820764, REVEL 0.12, MetaLR 0.07
- R43G (p.Arg43Gly), 1000Genomes rs146820764, ESP rs146820764, ExAC rs146820764, TOPMed rs146820764, REVEL 0.12, MetaLR 0.07
- R43H (p.Arg43His), rs779109570, ClinGen CA5312955, ClinVar RCV001169428, ClinVar RCV004032913, REVEL 0.11, MetaLR 0.06, Uncertain significance, Inborn genetic diseases; Orthostatic hypotension 1
- E44K (p.Glu44Lys), ExAC rs746901698, gnomAD rs746901698, REVEL 0.07, MetaLR 0.08, Uncertain significance, Inborn genetic diseases
- E44D (p.Glu44Asp), gnomAD 9-133636503-G-C, REVEL 0.04, MetaLR 0.11
- S45N (p.Ser45Asn), NCI-TCGA Cosmic COSV5504, MetaLR 0.09, MetaSVM -1.04, Variant assessed as somatic; moderate impact.
- S45R (p.Ser45Arg), gnomAD rs1482117226, REVEL 0.12, MetaLR 0.10
- S45S (p.Ser45Ser), rs770943084, gnomAD 9-133636506-C-T, CADD 4.39
- P46A (p.Pro46Ala), TOPMed rs1028535785, gnomAD rs1028535785, REVEL 0.06, MetaLR 0.08
- P46L (p.Pro46Leu), gnomAD rs944060307, REVEL 0.15, MetaLR 0.09
- P46S (p.Pro46Ser), TOPMed rs1028535785, gnomAD rs1028535785, REVEL 0.05, MetaLR 0.08
- P46T (p.Pro46Thr), TOPMed rs1028535785, gnomAD rs1028535785, REVEL 0.07, MetaLR 0.11
- P46P (p.Pro46Pro), gnomAD 9-133636509-C-T, CADD 4.83
- L47F (p.Leu47Phe), ExAC rs776251904, gnomAD rs776251904, REVEL 0.07, MetaLR 0.04
- L47H (p.Leu47His), Ensembl rs1832054426
- L47S (p.Leu47Ser), NCI-TCGA TCGA novel, MetaLR 0.09, MetaSVM -1.05, Variant assessed as somatic; high impact.
- L47L (p.Leu47Leu), gnomAD 9-133636512-C-T, CADD 3.03
- P48R (p.Pro48Arg), TOPMed rs1421390777, gnomAD rs1421390777, REVEL 0.24, MetaLR 0.21
- P48S (p.Pro48Ser), NCI-TCGA Cosmic COSV5504, REVEL 0.20, MetaLR 0.16, Variant assessed as somatic; moderate impact.
- P48P (p.Pro48Pro), gnomAD 9-133636515-C-A, CADD 2.48
- Y49C (p.Tyr49Cys), rs745685569, ClinGen CA5312959, NCI-TCGA Cosmic COSV5504, ClinVar RCV000685606, REVEL 0.30, AlphaMissense 0.21, Uncertain significance, Orthostatic hypotension 1
- Y49F (p.Tyr49Phe), rs745685569, ClinGen CA375407011, ClinVar RCV002737497, AlphaMissense 0.21, MetaLR 0.23, Uncertain significance, Inborn genetic diseases
- Y49I (p.Tyr49Ile), gnomAD 9-133636515-CT-C, CADD 24.90
- Y49D (p.Tyr49Asp), gnomAD 9-133636516-T-G, REVEL 0.44, MetaLR 0.26
- H50Y (p.His50Tyr), Ensembl rs78562123, MetaLR 0.14, MetaSVM -0.83
- H50H (p.His50His), rs1832054549, gnomAD 9-133636521-C-T, CADD 1.22
- I51M (p.Ile51Met), rs1832054587, ClinGen CA375407038, ClinVar RCV001169429, Ensembl rs1832054587, REVEL 0.13, MetaLR 0.18, Uncertain significance, Orthostatic hypotension 1
- I51N (p.Ile51Asn), gnomAD 9-133636523-T-A, REVEL 0.27, MetaLR 0.26
- P52A (p.Pro52Ala), ExAC rs769378064, gnomAD rs769378064
- P52L (p.Pro52Leu), NCI-TCGA Cosmic COSV5504, MetaLR 0.14, MetaSVM -0.86, Variant assessed as somatic; moderate impact.
- P52T (p.Pro52Thr), gnomAD 9-133636525-C-A, REVEL 0.18, MetaLR 0.15
- L53W (p.Leu53Trp), NCI-TCGA Cosmic COSV5504, Variant assessed as somatic; high impact.
- L53L (p.Leu53Leu), gnomAD 9-133636528-C-T, CADD 2.26
- D54Y (p.Asp54Tyr), NCI-TCGA TCGA novel, MetaLR 0.43, MetaSVM -0.08, Variant assessed as somatic; moderate impact.
- D54E (p.Asp54Glu), gnomAD 9-133636533-C-A, REVEL 0.34, MetaLR 0.24
- P55A (p.Pro55Ala), TOPMed rs1160873680, gnomAD rs1160873680, REVEL 0.29, MetaLR 0.32
- P55L (p.Pro55Leu), ExAC rs775127844, TOPMed rs775127844, gnomAD rs775127844, REVEL 0.48, MetaLR 0.28
- P55Q (p.Pro55Gln), rs775127844, NCI-TCGA Cosmic COSV5503, NCI-TCGA Cosmic COSV5504, ExAC rs775127844, REVEL 0.43, MetaLR 0.36, Variant assessed as somatic; moderate impact.
- P55R (p.Pro55Arg), ExAC rs775127844, TOPMed rs775127844, gnomAD rs775127844, REVEL 0.51, MetaLR 0.36
- P55S (p.Pro55Ser), NCI-TCGA Cosmic COSV9970, MetaLR 0.35, MetaSVM -0.31, Variant assessed as somatic; moderate impact.
- P55T (p.Pro55Thr), TOPMed rs1160873680, gnomAD rs1160873680, REVEL 0.39, MetaLR 0.35
- P55del (p.Pro55del), gnomAD 9-133636533-CCCG-, CADD 15.30
- P55P (p.Pro55Pro), gnomAD 9-133636536-G-T, CADD 0.72
- E56D (p.Glu56Asp), gnomAD rs1303774367, REVEL 0.03, MetaLR 0.11
- p.Glu56 Ser58del, gnomAD 9-133636534-CCGGA, CADD 15.80
- E56* (p.Glu56Ter), gnomAD 9-133636537-G-T, CADD 34.00
- E56E (p.Glu56Glu), rs1303774367, gnomAD 9-133636539-G-A, CADD 3.79
- G57A (p.Gly57Ala), ExAC rs533854976, TOPMed rs533854976, gnomAD rs533854976, REVEL 0.33, MetaLR 0.42
- G57R (p.Gly57Arg), TOPMed rs200561151, gnomAD rs200561151, REVEL 0.50, MetaLR 0.54
- G57V (p.Gly57Val), ExAC rs533854976, TOPMed rs533854976, gnomAD rs533854976, REVEL 0.53, MetaLR 0.49
- G57W (p.Gly57Trp), TOPMed rs200561151, gnomAD rs200561151, MetaLR 0.61, MetaSVM 0.30
- G57G (p.Gly57Gly), rs762193644, gnomAD 9-133636542-G-T, CADD 1.41
- S58F (p.Ser58Phe), ExAC rs750763532, TOPMed rs750763532, gnomAD rs750763532, REVEL 0.27, MetaLR 0.23
Public DBH analysis runs
- DBH analysis run — DBH (1,218 variants) — completed 2026-08-22